AVR late breaking trial presentation at London Valves, page-17

Jeffrey Popma, vice president and chief medical officer for the Coronary & Renal Denervation business and the Structural Heart & Aortic business, which are part of the Cardiovascular Portfolio at Medtronic, said in a news release. “Receiving CE Mark for the Evolut FX system highlights our commitment to providing minimally invasive treatment options globally for patients experiencing severe aortic stenosis.”

Jeffrey Popma was on our Ad Board before getting a great gig at MDT. He was a big fan of DurAVR. It’s interesting that the main focus on this upgrade seems to be deployment, positioning and Commissural alignment. Very quiet on EOA performance and Mean Gradients etc.